search
Back to results

Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry" (INOCAIT)

Primary Purpose

Cardiac Ischemia

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
not required
Sponsored by
IRCCS San Raffaele
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Cardiac Ischemia focused on measuring non-obstructive coronary artery disease

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical presentation of chronic ischemic heart disease (IHD), requiring coronary angiography for the diagnosis
  • Absence of obstructive CAD at coronary angiography
  • Age > 18 years
  • Ability to provide a valid informed consent to the study procedure at the time of baseline evaluation

Exclusion Criteria:

  • Clinical presentation of acute coronary syndrome (ACS) or cardiogenic shock
  • Presence of obstructive CAD with at least 1 significant coronary artery stenosis, defined as diameter stenosis >50% and FFR ≤0.80 (or iFR/RFR ≤0.89)
  • Previous coronary artery bypass grafting (CABG)
  • Left ventricular systolic dysfunction, defined as ejection fraction (EF) <40%
  • Severe valvular heart disease
  • Pregnant or breastfeeding women
  • Known hypersensitivity or contraindication to any of the drugs used for coronary physiology testing (adenosine, nitrates, acetylcholine)
  • Inability or unwillingness to provide a valid informed consent to the study procedure at the time of baseline evaluation

Sites / Locations

  • San Raffaele HospitalRecruiting
  • Azienda Ospedaliera Universitaria Federico II,
  • Fondazione Policlinico Universitario A. Gemelli IRCCS,Recruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

assessment of coronary physiology

Arm Description

This is a prospective, multicentric, non-randomized , single-arm , open label clinical study. Included patients will be studied with invasive functional tests performed during index coronary angiography. These will include FFR, instantaneous Wave-Free Ratio (iFR), Resting Ful-Cycle Ra-tio (RFR), CFR, IMR and provocative Acetylcholine test. After the diagnosis of vasospastic angina (VSA) or coronary microvascular dysfunction (CMD) is made, a stratified medical therapy will then be initiated according to the results of physiological assessment according to ESC guidelines and recent EAPCI expert consensus document .

Outcomes

Primary Outcome Measures

investigate the prevalence of INOCA in women vs. men
1. To investigate the prevalence of INOCA in women vs. men who are referred for a clinically indicated coronary angiography in three Centers in North-ern, Central and Southern Italy;
stratify in INOCA endotypes patients
2. to stratify in INOCA endotypes patients according to the presence or absence of alternative (i.e. non obstructive CAD) causes of myocardial ischemia detected during CA clinically indicated through physiology tests
implement a stratified therapy
3. to implement a stratified therapy in these patients considering the different INOCA endotypes and evaluate the impact on angina class and quality of life as well as cardiac hospitalization and coronary revascularization during 1 year follow up

Secondary Outcome Measures

Full Information

First Posted
October 8, 2021
Last Updated
February 9, 2022
Sponsor
IRCCS San Raffaele
Collaborators
Advice Pharma Group srl
search

1. Study Identification

Unique Protocol Identification Number
NCT05164640
Brief Title
Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry"
Acronym
INOCAIT
Official Title
Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry"
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2021 (Actual)
Primary Completion Date
November 15, 2022 (Anticipated)
Study Completion Date
April 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
IRCCS San Raffaele
Collaborators
Advice Pharma Group srl

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Prospective, interventional, multicentre, non-randomized, single-arm open-label study that aims to enroll 200 consecutive patients with suspected chronic ischemic heart disease in the absence of obstructive coronary artery disease (INOCA) at clinically indicated coronary angiography in 3 Italian centers. During coronary angiography, these patients will be simultaneously subjected to a functional and coronary physiology study (according to the methods reported below): Functional evaluation with fractional flow reserve (FFR), instantaneous wave-free ratio (iFR), Resting Full-Cycle Ratio (RFR) of angiographic stenosis> 50%; In the presence of coronary angiographic stenosis <50% or> 50% but in the presence of a negative functional assessment (FFR> 0.80 and iFR / RFR> 0.90), coronary flow reserve (CFR) and index of microvascular resistance (IMR) will be measured. IMR and CFR will be assessed using intra-coronary guidance; In the presence of CFR> 2.0 and IMR <25, tests with acetylcholine will also be performed in order to evaluate the possible presence of epicardial (focal or diffuse) or microvascular spasm.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Ischemia
Keywords
non-obstructive coronary artery disease

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
assessment of coronary physiology
Arm Type
Other
Arm Description
This is a prospective, multicentric, non-randomized , single-arm , open label clinical study. Included patients will be studied with invasive functional tests performed during index coronary angiography. These will include FFR, instantaneous Wave-Free Ratio (iFR), Resting Ful-Cycle Ra-tio (RFR), CFR, IMR and provocative Acetylcholine test. After the diagnosis of vasospastic angina (VSA) or coronary microvascular dysfunction (CMD) is made, a stratified medical therapy will then be initiated according to the results of physiological assessment according to ESC guidelines and recent EAPCI expert consensus document .
Intervention Type
Other
Intervention Name(s)
not required
Intervention Description
This a multicenter, prospective, non-randomized, single-arm, open label clinical study. This design doesn't include control vs intervention arms
Primary Outcome Measure Information:
Title
investigate the prevalence of INOCA in women vs. men
Description
1. To investigate the prevalence of INOCA in women vs. men who are referred for a clinically indicated coronary angiography in three Centers in North-ern, Central and Southern Italy;
Time Frame
3 year
Title
stratify in INOCA endotypes patients
Description
2. to stratify in INOCA endotypes patients according to the presence or absence of alternative (i.e. non obstructive CAD) causes of myocardial ischemia detected during CA clinically indicated through physiology tests
Time Frame
1 day (during physiology tests)
Title
implement a stratified therapy
Description
3. to implement a stratified therapy in these patients considering the different INOCA endotypes and evaluate the impact on angina class and quality of life as well as cardiac hospitalization and coronary revascularization during 1 year follow up
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical presentation of chronic ischemic heart disease (IHD), requiring coronary angiography for the diagnosis Absence of obstructive CAD at coronary angiography Age > 18 years Ability to provide a valid informed consent to the study procedure at the time of baseline evaluation Exclusion Criteria: Clinical presentation of acute coronary syndrome (ACS) or cardiogenic shock Presence of obstructive CAD with at least 1 significant coronary artery stenosis, defined as diameter stenosis >50% and FFR ≤0.80 (or iFR/RFR ≤0.89) Previous coronary artery bypass grafting (CABG) Left ventricular systolic dysfunction, defined as ejection fraction (EF) <40% Severe valvular heart disease Pregnant or breastfeeding women Known hypersensitivity or contraindication to any of the drugs used for coronary physiology testing (adenosine, nitrates, acetylcholine) Inability or unwillingness to provide a valid informed consent to the study procedure at the time of baseline evaluation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alaide Chieffo, MD
Phone
+39/02/2643/7331
Ext
7362
Email
chieffo.alaide@hsr.it
First Name & Middle Initial & Last Name or Official Title & Degree
Vega Rusconi, no
Phone
+39/02/2643/7331
Ext
7338
Email
rusconi.vega@hsr.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alaide Chieffo, MD
Organizational Affiliation
IRCCS San Raffaele
Official's Role
Principal Investigator
Facility Information:
Facility Name
San Raffaele Hospital
City
Milan
ZIP/Postal Code
20132
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alaide Chieffo, MD
Phone
+39/02/26437331
Ext
7362
Email
chieffo.alaide@hsr.it
First Name & Middle Initial & Last Name & Degree
Marco Ancona, MD
Phone
+39/02/26437331
Email
ancona.marco@hsr.it
Facility Name
Azienda Ospedaliera Universitaria Federico II,
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giovanni Esposito, MD
Phone
+390817463075
Email
espogiov@unina.it
First Name & Middle Initial & Last Name & Degree
alessandra spinelli, BSC
Phone
+390817462274
Email
alessandra.spinelli@unina.it
First Name & Middle Initial & Last Name & Degree
Anna Franzone, MD
First Name & Middle Initial & Last Name & Degree
Raffaele Piccolo, MD
First Name & Middle Initial & Last Name & Degree
Luigi Di Serafino, MD
First Name & Middle Initial & Last Name & Degree
Giuseppe Gargiulo, MD
Facility Name
Fondazione Policlinico Universitario A. Gemelli IRCCS,
City
Roma
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giampaolo Niccoli, MD
Phone
+39/333 459 8964
Email
gniccoli73@hotmail.it
First Name & Middle Initial & Last Name & Degree
Domenico Galante, MD
Phone
+393470635101
Email
domenico.galante1991@gmail.com
First Name & Middle Initial & Last Name & Degree
Antonio MA Leone, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry"

We'll reach out to this number within 24 hrs